ランキングに戻る

Resmed Inc (RMD)

割安
HealthcareMedical Instruments & SuppliesUnited States

ファンダメンタル

75

株価

$220.14

時価総額

$32.04B

パート1 · 企業の価値

概要

ResMed Inc. engages in the digital health and cloud-connected medical devices business in the United States and internationally. It operates in two segments, Sleep and Breathing Health, and Residential Care Software. The company offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. It also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

貸借対照表と流動性

売上高

$5.65B

直近12か月(2026/6/30まで)

純利益

$1.52B

直近12か月(2026/6/30まで)

フリーキャッシュフロー

$1.65B

自己資本合計

$6.59B

負債合計

$2.38B

流動比率

3.10

利払い倍率

-

負債/EBITDA

0.40

一株当たり利益(EPS)

売上高と純利益

フリーキャッシュフロー

収益内訳

財務推移表

利益率の推移

負債の推移

負債の重さ

成長率グリッド

成長率 — 売上高

適正価値の推定

一般的なケース割安

適正価値

$347.54

現在株価

$220.14

安全マージン

+36.7%

適正価値レンジ

$225.90 - $469.18

使用した評価手法間のばらつきであり、統計的に較正された信頼区間ではありません。

推定方法

アナリストの目標株価:$250.22
ディスカウンテッド・キャッシュフロー(DCF):$650.15
利益倍率(P/E):$188.04
グレアムの成長公式:$537.45
収益力価値(EPV):$117.55
正当化されたP/B:$95.10
配当割引モデル(ゴードン):$35.11
P/FFO(運用から生まれる資金):$191.29
中間サイクル利益:$183.10
売上高倍率:$153.05
アナリスト・コンセンサス:買い (13B / 12H / 2S)
直近の決算サプライズ:+1.09%

バリュエーション指標

P/E レシオ

21.20

ROE

23.1%

P/B レシオ

4.84

P/FCF

19.34

粗利益率

61.1%

ROIC

19.7%

収益性レーダー

価値創造(経済的モート)

ROIC

19.7%

WACC

8.5%

ROIC − WACC

+11.2 pp

ROICが資本コストを上回っています。企業は株主のために価値を創出しています。

ファンダメンタル分析基準

合格(19)

  • EPS shows upward trend
  • EPS CAGR 15.14%
  • Price CAGR 13.41%
  • ROIC 19.7%
  • Gross Margin 61.1%
  • P/FCF 19.34
  • Debt/Equity ratio
  • Operating Margin 33.4%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 23.9%
  • Revenue Growth 5Y 12.1%
  • PEG Ratio 0.79
  • Earnings Quality (OCF/NI) 1.19
  • Share Dilution -0.8%
  • Piotroski F-Score 7/9

不合格(7)

  • P/B Ratio 4.84
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Analyst Consensus 48% Buy
  • Earnings Surprise avg 0.8%
  • Net Margin Trend 26.9% vs 27.2%

データなし(2)

  • Dividend Payout NaN%
  • Interest Coverage

Piotroski F-スコア

7/9

財務健全性が高い

score
criteria

利益の質

1.19

高品質:利益はキャッシュに裏付けられている

株式希薄化

-0.8%

株式を買い戻している。株主に友好的

機関投資家の保有

ガバナンス

経営陣

氏名役職年齢
Mr. Michael J. Farrell BE, MBA, SMCEO & Chairman53
Dr. Peter C. Farrell A.M., B.E., BE (Hons), Ph.D., ScDFounder, Chair Emeritus & Non-Executive Director83
Mr. Michael J. RiderChief Legal Officer & Secretary67
Mr. Brett A. SandercockAdvisor58
Mr. Justin LeongChief Product Officer47
Mr. Aaron BloomerChief Financial Officer39
Mr. Alastair RobertsonChief Information Officer-
Ms. Sallilyn SchwartzChief Investor Relations Officer-
Mr. Jim EllisChief Compliance Officer-
Ms. Yvonne-Katrin PucknatChief Marketing Officer49

監査リスク

1

取締役会リスク

7

報酬リスク

4

株主権利リスク

3

パート2 · 株価と買い時

この部分は企業に価値があるかを判断するものではありません。ファンダメンタルズに納得したうえで、いつ買うかを選ぶためのものです。内容:テクニカル分析、ポテンシャル、過去のドローダウン、ガンマエクスポージャー。

書類

  • 年次報告書(10-K)

    事業内容、財務実績、リスクをまとめた年次の概要。

    提出日: 2026-08-13

    書類を見る
  • 四半期報告書(10-Q)

    直近3か月間の業績に関する最新情報。

    提出日: 2026-05-01

    書類を見る
  • 臨時報告書(8-K)

    経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

    提出日: 2026-09-01

    書類を見る

via SEC EDGAR

業績推移

via SEC EDGAR

Latest News

Recent headlines for RMD, sourced from Markets Gazette.

  • 3/10/2026POSITIVE
    3 Reasons Not to Sleep on ResMed Stock

    ResMed Inc., a prominent player in the sleep apnea and respiratory care market, is highlighted for its leadership in CPAP machines and other vital medical devices. The company's focus on improving respiratory health for millions globally positions it favorably within the healthcare sector. Investors are advised not to overlook ResMed's potential, suggesting a positive outlook driven by its established market position and ongoing innovation in medical technology. The company's products address a significant and growing health concern, underpinning its long-term value proposition.

  • 3/4/2026POSITIVE
    Here's How Much You Would Have Made Owning ResMed Stock In The Last 10 Years

    ResMed Inc. (RMD) stock has delivered exceptional performance over the past 10 years, offering investors significant returns. While the article doesn't provide exact figures, the title "Here's How Much You Would Have Made" implies consistent and profitable growth. This is crucial for investors assessing the long-term potential of the medical device and sleep-care solutions sector. Past performance, while not guaranteeing future results, indicates ResMed's strong ability to generate shareholder value, potentially driven by product innovation, market expansion, and sound management.

via Markets Gazette